Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00084604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Gastroesophageal Junction
Diffuse Adenocarcinoma of the Stomach
Intestinal Adenocarcinoma of the Stomach
Mixed Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage IIIA Gastric Cancer
Stage IIIB Gastric Cancer
Stage IIIC Gastric Cancer
Stage IV Gastric Cancer

Interventions

DRUG: irinotecan hydrochloride
BIOLOGICAL: bevacizumab
DRUG: cisplatin
PROCEDURE: computed tomography
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)